Animal Healthcare Is Barking Up the Right Tree
Idexx and Zoetis have profited from pandemic pets, but their valuations remain high.
Debbie Wang
Debbie Wang is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She covers the medical-device, diagnostics, and animal health industries. Previously, she was an associate director of equity analysis for Morningstar, leading the healthcare team.
Before joining Morningstar in 2002, Wang was a vice president and senior brand strategist for Leo Burnett. During her tenure at Leo Burnett, she led brand strategy on a variety of accounts, including Allstate, Amoco, McDonald's, Heinz, Smucker’s, Pepto-Bismol, and Celebrex.
Wang holds a bachelor’s degree in anthropology from Colgate University and a master’s degree in business administration from the University of Chicago Booth School of Business.
Latest
Medtronic Takes Another Shot
It's once again leading the field in the technology for treatment-resistant hypertension.
Looking for Gains in Treating Pain
Innovations in spinal cord stimulation bolster moats at Medtronic, Boston Scientific, and Abbott.
Abbott Reduces Outlook for Pandemic-Related Diagnostics
We’re not changing our $97 fair value estimate.
Will Robots Take Their Place in Orthopedics?
Robots are becoming more central to the orthopedic field, but widespread adoption still faces considerable hurdles.
We Like Zimmer's Pick for CEO
We think he’ll bring a much-needed new perspective to the company.
Stryker Posts Another Strong Quarter
With consistency that we rarely see in medical technology, Stryker has delivered another quarter of strong growth across all three of its segments.
Orthopedic Robots Have Promising Future
Robots from Stryker and Zimmer Biomet are worth a look.
Backlog Grows for Orthopedic Procedures
But the disruption caused by COVID-19 has little effect on the device industry’s moats.
Abbott's New Antigen Test is Big Step Forward for U.S.
We think Abbott's new antigen test will increase diagnostic testing capacity in the U.S. We are raising our fair value estimate for the narrow-moat company.
Coronavirus Vaccine Progress Accelerates
Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.
Turnaround Takes Hold at Zimmer
We see meaningful improvement and remain confident in the company's wide moat.
Putting LabCorp Under the Microscope
Will recent legislation affect its 2021?
Innovation Puts Medtronic in the Lead
The wide-moat company dominates medical technology.
Undervalued Medtronic Looks Like a Healthy Buy
The wide-moat medical device firm is well-positioned to leverage value-based reimbursement and risk-based contracts.
What Zoetis' Acquisition Means for Idexx
Wide-moat Zoetis' purchase of Abaxis makes strategic sense but doesn't threaten narrow-moat Idexx Labs.
Medtronic's Portfolio Is Unmatched
The wide-moat company leads the market in medical technology.
Medtronic's Dominance Results in Wide Moat
Few can match the company's pervasive presence in hospitals.
For Matters of the Heart (Valve), We Like Medtronic
We think this wide-moat device-maker has a lead in the transcatheter mitral valve market.
Is Healthcare Cost Sharing the Answer?
Policy research suggests consumers are not good at distinguishing high-value services from low-value.
What CEO Departure Means for Zimmer Biomet
The company's wide economic moat, which primarily stems from surgeon switching costs, remains intact.
A Healthcare Pick That's Moderately Shielded From Upheaval
We think Allergan is well positioned with a strong pipeline of specialty drugs and attractively undervalued today.
Zimmer Biomet's Regulatory Tussle
It will take many months for the wide-moat medical device firm to address the issues raised by the FDA, and this situation might drag on revenue growth in the near term, which could depress shares.
Healthcare Winners and Losers From Obamacare Repeal
The potential repeal of the Affordable Care Act will hurt hospitals, but we think some wide-moat pharma and biotech companies should be able to withstand the turbulence.
Insulet Shares Swoon on Insurer Decision, but Fair Value Is Unchanged
We think the firm is largely insulated from UnitedHealth's choice of Medtronic.
This Medical Device Maker Is Ankles and Shoulders Ahead
Stryker management has shown foresight by investing in orthopedic extremities and robotics, which will support its wide moat going forward.
Coke Still on Track; Shares Fully Valued
First-quarter revenue growth for the wide-moat beverage maker trailed our full-year estimates, but we expect growth to increase later in the year, writes Morningstar's Adam Fleck.
Steady Growth at J&J Reinforces Wide Moat, But Shares Overpriced
An anticipated slowdown in pharma giant’s drug business gives us some pause on the firm’s current valuation, but its long-term competitive advantages are intact.
4 Stocks to Profit From Obamacare’s Next Phase
Merck, Roche, Express Scripts, and LabCorp stand to benefit from an increased focus on cost control and improved outcomes.
4 Stocks to Profit From ACA's Next Phase
Merck, Roche, Express Scripts, and LabCorp stand to benefit from an increased focus on cost control and improved outcomes, says Morningstar's Debbie Wang.
Super-Wide Moat in the Making at Medtronic
The device maker's planned acquisition of Covidien will make it a force to be reckoned with.
Tides Turn for These Orthopedic Firms
Industry dynamics are shifting in the wake of Zimmer's Biomet acquisition.
No Surprises in Medtronic's Fiscal Third Quarter
The firm is on track to meet our full-year estimates, and our $60 per share fair value estimate and wide moat rating are intact.
Our Outlook for Health-Care Stocks
Med-tech multinationals look to the East for growth in China.
We See Opportunities for New Abbott to Raise Profitability
Sporting a narrow moat, Abbott is set for moderate growth, but the real opportunity for investors is in rising profitability.
Boston Scientific Falls Behind
Its lagging innovation has implications for the future.
Taking the Investment Pulse of Diagnostic Laboratories
This low-key health care niche could offer therapy for some portfolios.
Medical Device Regulation Revisited
Changes in regulation are casting shadows over the medical device industry.
Finding Moats in the Diagnostic Lab Industry
Diagnostic reference labs: Narrow moat firms have strong prospects.
A Shift in the Regulatory Winds for Medical Devices
A raft of issues could set the tone for the medical device industry going forward.
Our Favorite Health-Care Safe Havens
These eight health-care stocks have what it takes to weather the storm.
Our Favorite Health-Care Safe Havens
These eight health-care stocks have what it takes to weather the storm.
Our Outlook for Health-Care Stocks
Health-care companies are relatively unscathed by the market meltdown.
The Hazards of Health-Care Reform
Health-care reform is likely to be slow and painful.
Our Outlook for the Health-Care Sector
Political winds could cast a cloud over health-care companies.
Our Outlook for the Health-Care Sector
Health-care spending is likely insulated from larger economic bumpiness.
Our Outlook for the Health-Care Sector
We think big pharma's pipelines are looking healthier--it's time to buy.
Our Outlook for the Health-Care Sector
The pendulum may have swung too far at the FDA.
Our Outlook for the Health-Care Sector
Political and regulatory changes could sway biotech and drug stocks.